Levels of phosphorylated axonal neurofilament subunit H (pNfH) are increased in acute ischemic stroke

Journal of the Neurological Sciences

Volumn 304, Issue 1-2, 2011, Pages 117-121

  Singh, P ^a   Yan, J ^a   Hull, R ^b   Read, S ^b   O'Sullivan, J ^b   Henderson, R D ^b   Rose, S ^a   Greer, J M ^a   McCombe, P A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Acute ischemic stroke; Axonal injury; Biomarker; Neurofilament

Indexed keywords

PEPTIDES AND PROTEINS; PHOSPHORYLATED NEUROFILAMENT HEAVY PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN ISCHEMIA; CONTROLLED STUDY; DISABILITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STROKE; STROKE PATIENT;

AGED; AGED, 80 AND OVER; AXONS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; PHOSPHORYLATION; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 79953315948     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2011.01.025     Document Type: Article

References (44)

1. Glickman SW, Phillips S, Anstrom KJ, Laskowitz DT, Cairns CB. Discriminative capacity of biomarkers for acute stroke in the emergency department. J Emerg Med 2010;61: 333-43.
2. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 2009;40:77-85.
3. Rainer TH, Wong KS, Lam W, Lam NY, Graham CA, Lo YM. Comparison of plasma beta-globin DNA and S-100 protein concentrations in acute stroke. Clin Chim Acta 2007;376:190-6. (Pubitemid 44889254)
4. Fassbender K, Schmidt R, Schreiner A, Fatar M, Muhlhauser F, Daffertshofer M, et al. Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J Neurol Sci 1997;148:101-5. (Pubitemid 27149530)
5. Foerch C, Curdt I, Yan B, Dvorak F, Hermans M, Berkefeld J, et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry 2006;77:181-4. (Pubitemid 43220838)
6. Tomitori H, Usui T, Saeki N, Ueda S, Kase H, Nishimura K, et al. Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke. Stroke 2005;36:2609-13.
7. Allard L, Lescuyer P, Burgess J, Leung KY, Ward M, Walter N, et al. ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 2004;4:2242-51. (Pubitemid 39025324)
8. Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, Sanchez JC. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics 2004;3:66-72. (Pubitemid 38697105)
9. Ramos-Fernandez M, Bellolio MF, Stead LG. Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis 2010.
10. Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke 2008;39:2902-9.
11. Foerch C, Montaner J, Furie KL, Ning MM, Lo EH. Invited article: searching for oracles? Blood biomarkers in acute stroke. Neurology 2009;73:393-9.
12. El HN, Laskowitz DT. Clinical application of blood biomarkers in cerebrovascular disease. Expert Rev Neurother 2010;10:189-203.
13. Boylan K, Yang C, Crook J, Overstreet K, Heckman M, Wang Y, et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem 2009;111:1182-91.
14. Shaw G, Yang C, Ellis R, Anderson K, Parker Mickle K, Scheff S, et al. Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem Biophys Res Commun 2005;336:1268-77. (Pubitemid 41383458)
15. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183-98. (Pubitemid 40804835)
16. Goldstein ME, Sternberger NH, Sternberger LA. Phosphorylation protects neurofilaments against proteolysis. J Neuroimmunol 1987;14:149-60. (Pubitemid 17018117)
17. Huh JW, Laurer HL, Raghupathi R, Helfaer MA, Saatman KE. Rapid loss and partial recovery of neurofilament immunostaining following focal brain injury in mice. Exp Neurol 2002;175:198-208. (Pubitemid 34507922)
18. Aronowski J, Cho KH, Strong R, Grotta JC. Neurofilament proteolysis after focal ischemia; when do cells die after experimental stroke? J Cereb Blood Flow Metab 1999;19:652-60.
19. Sellner J, Petzold A, Sadikovic S, Esposito L, Weber MS, Heider P, et al. The value of the serum neurofilament protein heavy chain as a biomarker for peri-operative brain injury after carotid endarterectomy. Neurochem Res 2009;34:1969-74.
20. Lewis SB, Wolper RA, Miralia L, Yang C, Shaw G. Detection of phosphorylated NF-H in the cerebrospinal fluid and blood of aneurysmal subarachnoid hemorrhage patients. J Cereb Blood Flow Metab 2008;28:1261-71. (Pubitemid 351733343)
21. Yan J, Greer JM, Etherington K, Cadigan GP, Cavanagh H, Henderson RD, et al. Immune activation in the peripheral blood of patients with acute ischemic stroke. J Neuroimmunol 2009;206:112-7.
22. Brott T, Adams Jr HP, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-70. (Pubitemid 19188240)
23. Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke 1988;19: 1497-500. (Pubitemid 19005804)
24. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med J 1965;14:61-5.
25. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-6.
26. Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(Suppl 1):S208-19.
27. Mead GE, Lewis SC, Wardlaw JM, Dennis MS, Warlow CP. How well does the Oxfordshire community stroke project classification predict the site and size of the infarct on brain imaging? J Neurol Neurosurg Psychiatry 2000;68:558-62.
28. Kobayashi A, Wardlaw JM, Lindley RI, Lewis SC, Sandercock PA, Czlonkowska A. Oxfordshire community stroke project clinical stroke syndrome and appearances of tissue and vascular lesions on pretreatment ct in hyperacute ischemic stroke among the first 510 patients in the Third International Stroke Trial (IST-3). Stroke 2009;40:743-8.
29. Ovbiagele B, Saver JL. Day-90 acute ischemic stroke outcomes can be derived from early functional activity level. Cerebrovasc Dis 2010;29:50-6.
30. Saunders DE, Clifton AG, Brown MM. Measurement of infarct size using MRI predicts prognosis in middle cerebral artery infarction. Stroke 1995;26:2272-6.
31. Uyttenboogaart M, Stewart RE, Vroomen PC, De KJ, Luijckx GJ. Optimizing cutoff scores for the Barthel index and the modified Rankin scale for defining outcome in acute stroke trials. Stroke 2005;36:1984-7. (Pubitemid 41266538)
32. Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;66:852-6. (Pubitemid 43739759)
33. Aronowski J, Cho KH, Strong R, Grotta JC. Neurofilament proteolysis after focal ischemia; when do cells die after experimental stroke? J Cereb Blood Flow Metab 1999;19:652-60.
34. Kelly PJ, Morrow JD, Ning M, Koroschetz W, Lo EH, Terry E, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 2008;39:100-4.
35. Wunderlich MT, Lins H, Skalej M, Wallesch CW, Goertler M. Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 2006;108:558-63. (Pubitemid 44189097)
36. Reynolds MA, Kirchick HJ, Dahlen JR, Anderberg JM, McPherson PH, Nakamura KK, et al. Early biomarkers of stroke. Clin Chem 2003;49:1733-9. (Pubitemid 37194242)
37. Mamere AE, Saraiva LA, Matos AL, Carneiro AA, Santos AC. Evaluation of delayed neuronal and axonal damage secondary tomoderate and severe traumatic brain injury using quantitative MR imaging techniques. AJNR Am J Neuroradiol 2009;30:947-52.
38. Smith DH, Chen XH, Pierce JE, Wolf JA, Trojanowski JQ, Graham DI, et al. Progressive atrophy and neuron death for one year following brain trauma in the rat. J Neurotrauma 1997;14:715-27. (Pubitemid 27479412)
39. Lorberboym M, Lampl Y, Sadeh M. Correlation of 99mTc-DTPA SPECT of the blood-brain barrier with neurologic outcome after acute stroke. J Nucl Med 2003;44:1898-904. (Pubitemid 40022134)
40. Kastrup A, Engelhorn T, Beaulieu C, de CA, Moseley ME. Dynamics of cerebral injury, perfusion, and blood-brain barrier changes after temporary and permanent middle cerebral artery occlusion in the rat. J Neurol Sci 1999;166:91-9. (Pubitemid 29339079)
41. McCombe PA, Read SJ. Immune and inflammatory responses to stroke: good or bad? Int J Stroke 2008;3:254-65.
42. Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, et al. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med 2009;15:946-50.
43. Brait VH, Jackman KA, Walduck AK, Selemidis S, Diep H, Mast AE, et al. Mechanisms contributing to cerebral infarct size after stroke: gender, reperfusion, T lymphocytes, and Nox2-derived superoxide. J Cereb Blood Flow Metab 2010;30:1306-17.
44. Czech B, Pfeilschifter W, Mazaheri-Omrani N, Strobel MA, Kahles T, Neummann-Hafelin T, et al. The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun 2009;389:251-6.